Table 5.
Efficacy of warfarin, enoxaparin, dabigatran or rivaroxaban for the prophylaxis of VTE and SPAF
| RR, Dabigatran vs Warfarin (95% CI)27 | RR, Dabigatran vs Enoxaparin (95% CI)30 | RR, Rivaroxaban vs Warfarin (95% CI)31 | RR, Rivaroxaban vs Enoxaparin (95% CI)32 | Incidence (% n/N)29-32 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy | VTE | Stroke | VTE | Stroke | VTE | Stroke | VTE | Stroke | VTE | Stroke |
| Total VTE/stroke and all-cause mortality | 0.94 | 0.88 | 0.97 | - | 0.71 | 0.80 | 0.68 | - | 37.7 | 3.9 |
| (0.76-1.85) | (0.58-1.39) | (0.83-1.13) | (0.55-2.33) | (0.60-1.05) | (0.71-5.67) | (193/512) | (87/2331) | |||